Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 24;32:09636897231187996. doi: 10.1177/09636897231187996

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Morphological changes of organoids after PARPi treatment. (A) Representative bright field images of organoids after PARPi treatment were shown. The patient-derived organoids were inhibited by high-concentration PARPi, and treating for a long time did not represent a significant difference. Scale bars, 200 μm. (B) Representative images of Ki67 and DAPI immunofluorescence staining of adherent cells. Three indicated groups were divided to investigate dose sensitivity. (C) The expression level of ovarian cancer marker Ki67 and proportion of Ki67/DAPI in adherent cells after PARPi treatment was measured. Data are presented as the mean ± SEM (n = 3; *P < 0.05; **P < 0.01; ***P < 0.001; student’s test).